Comparative analysis of lysophospholipid metabolism profiles and clinical characteristics in patients with high vs. low C-reactive protein levels in acute exacerbations of chronic obstructive pulmonary disease

被引:2
作者
Zhou, Qiqiang [1 ]
Chang, Chun [1 ,2 ]
Wang, Yating [1 ]
Gai, Xiaoyan [1 ,2 ]
Chen, Yahong [1 ,2 ]
Gao, Xu [3 ]
Liang, Ying [1 ,2 ]
Sun, Yongchang [1 ,2 ]
机构
[1] Peking Univ Third Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Res Ctr Chron Airway Dis, Beijing, Peoples R China
[3] Peking Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth Sci, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Chronic obstructive pulmonary disease; Acute exacerbation; C-reactive protein; Lipidomics; Lysophospholipids; Systemic inflammation; INFLAMMATORY RESPONSE; ENDOTHELIAL-CELLS; LYSOPHOSPHATIDYLCHOLINE; CRP; ASSOCIATION; MORTALITY; OUTCOMES; RELEASE; MARKER;
D O I
10.1016/j.cca.2024.119816
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The precise role of lysophospholipids (LysoPLs) in the pathogenesis of acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) remains unclear. In this study, we sought to elucidate the differences in serum LysoPL metabolite profiles and their correlation with clinical features between patients with low versus high CRP levels. Methods: A total of 58 patients with AECOPD were enrolled in the study. Patients were classified into two groups: low CRP group (CRP < 20 mg/L, n = 34) and high CRP group (CRP >= 20 mg/L, n = 24). Clinical data were collected, and the LysoPL metabolite profiles were analyzed using Liquid Chromatography-Mass Spectrometry (LC-MS) and identified by matching with the LipidBlast library. Results: Nineteen differential LysoPLs were initially identified through Student's t-test (p < 0.05 and VIP > 1). Subsequently, four LysoPLs, LPC(16:0), LPE(18:2), LPC(22:0), and LPC(24:0), were identified by FDR adjustment (adjusted p < 0.05). These four lysoPLs had a significant negative correlation with CRP. Integrative analysis revealed that LPC (16:0) and LPC (22:0) correlated with less hypercapnic respiratory failure and ICU admission. Conclusion: AECOPD patients with high CRP levels demonstrated a distinctive LysoPL metabolism profile, with LPC (16:0), LPE(18:2), LPC(22:0), and LPC(24:0) being the most significantly altered lipid molecules. These alterations were associated with poorer clinical outcomes.
引用
收藏
页数:11
相关论文
共 60 条
[1]   Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia [J].
Arshad, Haroon ;
Alfonso, Juan Carlos Lopez ;
Franke, Raimo ;
Michaelis, Katina ;
Araujo, Leonardo ;
Habib, Aamna ;
Zboromyrska, Yuliya ;
Luecke, Eva ;
Strungaru, Emilia ;
Akmatov, Manas K. ;
Hatzikirou, Haralampos ;
MeyerHermann, Michael ;
Petersmann, Astrid ;
Nauck, Matthias ;
Broenstrup, Mark ;
Bilitewski, Ursula ;
Abel, Laurent ;
Sievers, Jorg ;
Vila, Jordi ;
Illig, Thomas ;
Schreiber, Jens ;
Pessler, Frank .
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
[2]   Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP) [J].
Banoei, Mohammad M. ;
Vogel, Hans J. ;
Weljie, Aalim M. ;
Yende, Sachin ;
Angus, Derek C. ;
Winston, Brent W. .
CRITICAL CARE, 2020, 24 (01)
[3]   C-reactive protein levels in patients with chronic obstructive pulmonary disease: Role of infection [J].
Bircan, Ahmet ;
Gokirmak, Munire ;
Kilic, Ozkan ;
Ozturk, Onder ;
Akkaya, Ahmet .
MEDICAL PRINCIPLES AND PRACTICE, 2008, 17 (03) :202-208
[4]  
Blom M, 1998, BLOOD, V91, P3037
[5]   Raised CRP levels mark metabolic and functional impairment in advanced COPD [J].
Broekhuizen, R ;
Wouters, EFM ;
Creutzberg, EC ;
Schols, AMWJ .
THORAX, 2006, 61 (01) :17-22
[6]   C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations [J].
Butler, Christopher C. ;
Gillespie, David ;
White, Patrick ;
Bates, Janine ;
Lowe, Rachel ;
Thomas-Jones, Emma ;
Wootton, Mandy ;
Hood, Kerenza ;
Phillips, Rhiannon ;
Melbye, Hasse ;
Llor, Carl ;
Cals, Jochen W. L. ;
Naik, Gurudutt ;
Kirby, Nigel ;
Gal, Micaela ;
Riga, Evgenia ;
Francis, Nick A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :111-120
[7]   Definition and Nomenclature of Chronic Obstructive Pulmonary Disease Time for Its Revision [J].
Celli, Bartolome ;
Fabbri, Leonardo ;
Criner, Gerard ;
Martinez, Fernando J. ;
Mannino, David ;
Vogelmeier, Claus ;
Montes de Oca, Maria ;
Papi, Alberto ;
Sin, Don D. ;
Han, MeiLan K. ;
Agusti, Alvar .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 206 (11) :1317-1325
[8]   An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations The Rome Proposal [J].
Celli, Bartolome R. ;
Fabbri, Leonardo M. ;
Aaron, Shawn D. ;
Agusti, Alvar ;
Brook, Robert ;
Criner, Gerard J. ;
Franssen, Frits M. E. ;
Humbert, Marc ;
Hurst, John R. ;
O'Donnell, Denis ;
Pantoni, Leonardo ;
Papi, Alberto ;
Rodriguez-Roisin, Roberto ;
Sethi, Sanjay ;
Torres, Antoni ;
Vogelmeier, Claus F. ;
Wedzicha, Jadwiga A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (11) :1251-1258
[9]   Lipid metabolism in chronic obstructive pulmonary disease [J].
Chen, Haipin ;
Li, Zhouyang ;
Dong, Lingling ;
Wu, Yinfang ;
Shen, Huahao ;
Chen, Zhihua .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 :1009-1018
[10]   Lysophosphatidylcholine as a prognostic marker in community-acquired pneumonia requiring hospitalization: a pilot study [J].
Cho, W. H. ;
Yeo, H. J. ;
Yoon, S. H. ;
Lee, S. E. ;
Jeon, D. S. ;
Kim, Y. S. ;
Lee, S. J. ;
Jo, E. J. ;
Mok, J. H. ;
Kim, M. H. ;
Kim, K. U. ;
Lee, K. ;
Park, H. K. ;
Lee, M. K. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (02) :309-315